22 Mar 2017 14:55
INTERNATIONAL BIOTECHNOLOGY TRUST PLC (the Company)
Portfolio Update as at 28 February 2017
Net Assets | £248m |
Net Assets per share | 661p |
Share price | 590p |
Total value of unquoted investments | £24m |
Total number of portfolio companies | 87 |
Top Ten Holdings
Company Name | % NAV |
Celgene | 7.6 |
Incyte | 7.2 |
Biogen | 7.0 |
Alexion | 5.3 |
Genmab | 4.3 |
Amgen | 4.3 |
Regeneron | 4.2 |
Shire | 4.0 |
Illumina | 3.3 |
Vertex | 3.2 |
----------- | |
Total | 50.4 |
Geographical Allocation | % NAV |
US & Canada | 85 |
Europe & UK | 15 |
----------- | |
Total | 100 |
Quoted/Unquoted Allocation | % NAV |
Quoted | 90 |
Unquoted | 10 |
----------- | |
Total | 100 |
NAV % Market Cap | % NAV |
Large Cap >USD10BN | 61 |
Mid Cap =USD1-10BN | 19 |
Small Cap | 20 |
----------- | |
Total | 100 |
NAV % by Therapeutic Areas | % NAV |
Oncology | 39 |
Orphan | 13 |
CNS | 9 |
Inflammation | 8 |
Ophthalmology | 6 |
Medtech | 2 |
Other | 23 |
----------- | |
Total | 100 |
BNP Paribas Secretarial Services Limited
Company Secretary
22 MARCH 2017
Int.biotech. (IBT)